文献速递遗传性与小管间质肾病

达格列净在糖原贮积病1b型小鼠模型中预防肾脏糖原蓄积并改善肾近端小管细胞功能

Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b.
PubMed 文献 · J Am Soc Nephrol · 2022-07-12

在GSD1b诱导型小鼠模型(TM-G6PT-/-)中,G6PT抑制上调己糖激酶-I,使重吸收葡萄糖更多进入细胞内代谢并导致糖原蓄积。给予SGLT2抑制剂达格列净可预防糖原蓄积、促进糖原分解并恢复近端小管功能标志物表达,从而改善肾脏形态。作者认为该结果为达格列净用于GSD1b患者提供了概念验证。

要点

  • G6PT抑制上调近端小管己糖激酶-I,增加重吸收葡萄糖的细胞内代谢利用。
  • 达格列净在TM-G6PT-/-小鼠中预防肾脏糖原蓄积并改善肾脏形态。
  • 达格列净恢复NaPi2A、NHE3、SGLT2、GLUT2和AQP1等近端小管功能标志物表达。

核心结论

  • 作者提供达格列净在GSD1b小鼠中保护肾脏功能的概念验证,该发现可能成为将该药重新用于治疗GSD1b患者的基础。

研究设计与样本

  • 研究使用GSD1b诱导型小鼠模型TM-G6PT-/-,并给予SGLT2抑制剂达格列净以限制葡萄糖进入近端小管细胞。

主要发现

  • 在近端小管细胞中,G6PT抑制刺激己糖激酶-I的上调及活性,增加重吸收葡萄糖用于细胞内代谢的可利用量。
  • 达格列净通过促进代谢从糖原合成转向糖原分解,并恢复主要近端小管功能标志物的表达水平,从而预防糖原蓄积并改善肾脏形态。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in SLC37A4, which encodes the intracellular glucose transporter G6PT, cause the rare glycogen storage disease type 1b (GSD1b). A long-term consequence of GSD1b is kidney failure, which requires KRT. The main protein markers of proximal tubule function, including NaPi2A, NHE3, SGLT2, GLUT2, and AQP1, are downregulated as part of the disease phenotype. METHODS: We utilized an inducible mouse model of GSD1b, TM-G6PT-/-, to show that glycogen accumulation plays a crucial role in altering proximal tubule morphology and function. To limit glucose entry into proximal tubule cells and thus to prevent glycogen accumulation, we administered an SGLT2-inhibitor, dapagliflozin, to TM-G6PT-/- mice. RESULTS: In proximal tubule cells, G6PT suppression stimulates the upregulation and activity of hexokinase-I, which increases availability of the reabsorbed glucose for intracellular metabolism. Dapagliflozin prevented glycogen accumulation and improved kidney morphology by promoting a metabolic switch from glycogen synthesis toward lysis and by restoring expression levels of the main proximal tubule functional markers. CONCLUSION: We provide proof of concept for the efficacy of dapagliflozin in preserving kidney function in GSD1b mice. Our findings could represent the basis for repurposing this drug to treat patients with GSD1b.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. D'Acierno M, Resaz R, Iervolino A, et al. Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b. J Am Soc Nephrol. 2022. PMID: 35820785. doi:10.1681/ASN.2021070935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。